Stereotactic Body Radiotherapy for High-Risk Localized Carcinoma of the Prostate (SHARP) Consortium: Analysis of 344 Prospectively Treated Patients
Ritchell van Dams(Brigham and Women's Hospital), Amar U. Kishan(University of California, Los Angeles), Patrick A. Kupelian, Donald B. Fuller(Genesis HealthCare), Simeng Suy(Georgetown University), Andrew Loblaw(Sunnybrook Health Science Centre), Vedang Murthy(Homi Bhabha National Institute), Sean P. Collins(Wayne State University), Nicholas G. Nickols(VA Greater Los Angeles Healthcare System), Tahmineh Romero(University of California, Los Angeles), Kevin L. Stephans(Cleveland Clinic), Michael L. Steinberg(University of California, Los Angeles), Nima Aghdam(Georgetown University), Ye Yuan(Peking University), Alan J. Katz(Winthrop-University Hospital), Tejshri Telkhade(Tata Memorial Hospital), Naomi Jiang(University of California, Los Angeles), Tommy Jiang(Stanford Medicine)
International Journal of Radiation Oncology*Biology*Physics
January 23, 2021
Cited by 63
Related Papers
The SGLT2 inhibitor empagliflozin in patients hospitalized for acute heart failure: a multinational randomized trial
|Nature Medicine|2022|889
The Lancet Commission on prostate cancer: planning for the surge in cases
|The Lancet|2024|694
Management of Patients with Advanced Prostate Cancer: The Report of the Advanced Prostate Cancer Consensus Conference APCCC 2017
|European Urology|2017|644